{
      "ptx_code": "PTX150",
      "chem_name": "Flecainide",
      "casrn": "54143-55-4",
      "dtxsid": "DTXSID8023054",
      "smiles": "FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1",
      "inchikey": "DJBNUMBKLMJRSA-UHFFFAOYSA-N",
      "label": "PTX150 | Flecainide",
      "drugbank_id": "DB01195",
      "use_class": "Pharmaceutical",
      "tox_class": "Cardiotoxicity; Neurotoxicity; Hepatotoxicity",
      "chem_name_user": "Flecainide",
      "mw_g_mol": "414.348",
      "solubility_h2o_mol_liter": "0.000363992",
      "source_solubility_h2o": "COMPTOX (OPERA)",
      "henry_coefficient_atm_m3_mol": "8.6017e-09",
      "source_henry": "COMPTOX",
      "log_kaw_kh_rt": "6.45372538016389",
      "source_kaw": "LSER eq 1 exp. Descriptors",
      "pka_acid": "13.47",
      "pka_base": "9.66",
      "source_pka": "ACD pKa/GALAS",
      "log_kow_liter_liter": "3.78",
      "source_kow": "",
      "log_dlipw_ph74_liter_liter": "1.71906720975011",
      "source_dlipw": "LSER",
      "freely_dissolved_fraction": "0.483492777773593",
      "density_kg_liter": "",
      "source_density": "COMPTOX",
      "baseline_drerio": "3297.03427790676",
      "baseline_dmagna": "1304.41106577577",
      "baseline_celegans": "2829.74573397579",
      "baseline_xlaevis": "684.813556650373",
      "baseline_dmelanogaster": "11585.8815886865",
      "baseline_cells": "0.000979501102644511",
      "baseline_cells_generic_micromole_liter_free_ec10": "0.000473581708949891",
      "moa_drugbank": "Flecainide blocks fast inward sodium channels and slowly unbinds during diastole, prolonging the refractory period of the heart.[A186931] This blockade also shortens the duration of action potentials through the Purkinjie fibers.[A186931] Flecainide also prevents delayed rectifier potassium channels from opening, lengthening the action potential through ventricular and atrial muscle fibers.[A186931] Finally, flecainide also blocks ryanodine receptor opening, reducing calcium release from sarcoplasmic reticulum, which reduces depolarization of cells.[A186931]",
      "protein_binding": "Flecainide is 40% bound to protein in serum, mainly to alpha-1-acid glycoprotein and minorly to serum albumin.[A186853,L5056]",
      "moa_t3db": "Flecainide acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers.",
      "aop": [],
      "targets": [
            "Potassium voltage-gated channel subfamily A member 5",
            "Potassium voltage-gated channel subfamily H member 2",
            "Sodium channel protein type 4 subunit alpha",
            "Sodium channel protein type 5 subunit alpha"
      ]
}